Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1:156–64.

Article  PubMed  Google Scholar 

Song BH, Cha B, Park JS, Jeong S, Lee DH. Effects of microvascular invasion on clinical outcomes after resection with curative intent for cholangiocarcinoma. Med (Baltim). 2020;99:e23668.

Article  CAS  Google Scholar 

Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2019;394:1145–58.

Article  PubMed  PubMed Central  Google Scholar 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. CA Cancer J Clin. 2016;66:115–32. Cancer statistics in China, 2015.

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  PubMed  Google Scholar 

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA, W., Board E. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.

Article  PubMed  Google Scholar 

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.

Article  PubMed  Google Scholar 

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111.

Article  CAS  PubMed  Google Scholar 

Ramai D, Ofosu A, Lai JK, Reddy M, Adler DG. Combined Hepatocellular Cholangiocarcinoma: a Population-based retrospective study. Am J Gastroenterol. 2019;114:1496–501.

Article  PubMed  Google Scholar 

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Feliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J. Maithel, adjuvant therapy for resected biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:1015–27.

Article  PubMed  Google Scholar 

Affo S, Yu LX, Schwabe RF. The role of Cancer-Associated fibroblasts and fibrosis in Liver Cancer. Annu Rev Pathol. 2017;12:153–86.

Article  CAS  PubMed  Google Scholar 

Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95–103.

Article  PubMed  Google Scholar 

Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, Ayav A, Campillo-Gimenez B, Beuzit L, Pracht M, Lievre A, Le Sourd S, Boudjema K, Rolland Y, Boucher E, Garin E. Radioembolization Plus Chemotherapy for First-line treatment of locally Advanced Intrahepatic Cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51–9.

Article  PubMed  Google Scholar 

Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. Cancer Chemother Pharmacol. 2016;77:109–14.

Article  CAS  PubMed  Google Scholar 

Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, Kim JS, Thomas CR Jr. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29:4627–32.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M, Shen F. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.

Article  PubMed  Google Scholar 

Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, Andre T, Chibaudel B, Faivre S. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncol. 2016;55:1168–74.

Article  CAS  PubMed  Google Scholar 

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3. O’Dwyer, Nab-Paclitaxel and Gemcitabine as First-line treatment of Advanced or Metastatic Cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:1707–12.

Article  PubMed  PubMed Central  Google Scholar 

Ji GW, Zhu FP, Zhang YD, Liu XS, Wu FY, Wang K, Xia YX, Zhang YD, Jiang WJ, Li XC, Wang XH. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol. 2019;29:3725–35.

Article  PubMed  Google Scholar 

Valle. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345–348.

Article  PubMed  Google Scholar 

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in biliary tract cancers. Cancer Discov. 2017;7:943–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jheng GW, Hur SS, Chang CM, Wu CC, Cheng JS, Lee HH, Chung BC, Wang YK, Lin KH, Del Alamo JC, Chien S, Tsai JW. Lis1 dysfunction leads to traction force reduction and cytoskeletal disorganization during cell migration. Biochem Biophys Res Commun. 2018;497:869–75.

Article  CAS  PubMed  Google Scholar 

Yang R, Chen Y, Tang C, Li H, Wang B, Yan Q, Hu J, Zou S. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. BMC Cancer. 2014;14:917.

Article  PubMed  PubMed Central  Google Scholar 

Lu X, Wang J, Dong B, Wang L, Liu Y. Exosomal mir-93-5p from cancer-associated fibroblasts confers malignant phenotypes on bladder cancer cells by targeting PAFAH1B1. Anticancer Drugs. 2023;34:439–50.

Article  CAS  PubMed  Google Scholar 

Chodary Khameneh S, Razi S, Shamdani S, Uzan G, Naserian S. Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer. Sci Rep. 2022;12:2990.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu W, Yu S, Xiong J, Long J, Zheng Y, Sang X. CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. Aging. 2020;12:1047–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Y, Yang J, Wang Y, Tang Z, Liu S, Tang Y. MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6. Arch Biochem Biophys. 2020;686:108367.

Article  CAS  PubMed  Google Scholar 

Chen C, Jiang J, Fang M, Zhou L, Chen Y, Zhou J, Song Y, Kong G, Zhang B, Jiang B, Li H, Peng C, Liu S. MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma. J Cancer. 2020;11:3216–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lendvai G, Szekerczes T, Illyes I, Dora R, Kontsek E, Gogl A, Kiss A, Werling K, Kovalszky I, Schaff Z, Borka K. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis, Pathol Oncol Res 26 (2020) 3–15.

Ling XH, Fu H, Chen ZY, Lu JM, Zhuo YJ, Chen JH, Zhong WD, Jia Z. miR–505 suppresses prostate cancer progression by targeting NRCAM. Oncol Rep. 2019;42:991–1004.

CAS  PubMed  PubMed Central  Google Scholar 

Ren L, Yao Y, Wang Y, Wang S. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R. Biosci Rep 39 (2019).

Tang H, Lv W, Sun W, Bi Q, Hao Y. miR–505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT–NFkappaB pathway in NSCLC cells. Int J Mol Med. 2019;43:1203–16.

CAS  PubMed  Google Scholar 

Chen Y, Bian L, Zhang Y. MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol. 2018;70:937–51.

Article  CAS  PubMed  Google Scholar 

Li X, Liu L, Li R, Wu A, Lu J, Wu Q, Jia J, Zhao M, Song H. Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice. J Biol Chem. 2018;293:5160–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing Z, Tang X, Gao Y, Da L, Song H, Wang S, Tiollais P, Li T, Zhao M. The human LIS1 is downregulated in hepatocellular carcinoma and plays a tumor suppressor function. Biochem Biophys Res Commun. 2011;409:193–9.

Article  CAS